U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07766473) titled 'First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)' on July 21.
Brief Summary: This is a first-in-human clinical trial evaluating the safety and tolerability of BETA-TT8 Ophthalmic Gel in people with wet age-related macular degeneration (AMD). Approximately 24 participants with stable wet AMD who have previously received at least three anti- Vascular Endothelial Growth Factor (anti -VEGF) injections will use the eye gel for up to 12 weeks at one of three dosing schedules (once, twice, or three times daily). Standard anti-VEGF treatment (aflibercept) will remain available if needed during the study. Part...